Should Novavax Be Worried About Losing IP Rights?

On Wednesday, President Joe Biden announced that his administration supported the waiver of intellectual property (IP) rights for COVID-19 vaccines in negotiations at the World Trade Organization (WTO). Is this a danger for Novavax (NASDAQ:NVAX) investors? Not really.

One important point is that Biden's announcement is not a law or a verdict in a patent case. It's the announcement of a negotiating position at talks at the WTO. So far, Novavax hasn't lost anything. And WTO agreements require the consensus of all 164 member countries.